Evidence map›Paper›PMID 37852977›Full record

ArticleCell death & disease2023

MacroH2A1.1 as a crossroad between epigenetics, inflammation and metabolism of mesenchymal stromal cells in myelodysplastic syndromes.

C Giallongo, I Dulcamare, S Giallongo, A Duminuco, D Pieragostino, M C Cufaro, A M Amorini, G Lazzarino, A Romano, N Parrinello and 12 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 2 countries.

C Giallongo *Department of Medical, Surgical Sciences and Advanced Technologies "G.F. Ingrassia", University of Catania, Catania, Italy.ORCID 0000-0002-5047-7515
I Dulcamare *Division of Hematology, AOU Policlinico, Catania, Italy.
S GiallongoDepartment of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy. sebastiano.giall@gmail.com.
A DuminucoDivision of Hematology, AOU Policlinico, Catania, Italy.
D PieragostinoDepartment of Innovative Technologies and Medicine & Odontoiatry, University G. D'Annunzio, Chieti-Pescara, Italy.
M C CufaroDepartment of Innovative Technologies and Medicine & Odontoiatry, University G. D'Annunzio, Chieti-Pescara, Italy.
A M AmoriniDepartment of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
G LazzarinoDepartmental Faculty of Medicine and Surgery, UniCamillus-Saint Camillus International University of Health and Medical Sciences, Rome, Italy.
A RomanoDepartment of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy.
N ParrinelloDivision of Hematology, AOU Policlinico, Catania, Italy.
M Di RosaDepartment of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
G BroggiDepartment of Medical, Surgical Sciences and Advanced Technologies "G.F. Ingrassia", University of Catania, Catania, Italy.ORCID 0000-0003-2576-6523
R CaltabianoDepartment of Medical, Surgical Sciences and Advanced Technologies "G.F. Ingrassia", University of Catania, Catania, Italy.
M CaragliaDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.ORCID 0000-0003-2408-6091
M ScrimaLaboratory of Precision and Molecular Oncology, Biogem Scarl, Institute of Genetic Research, Ariano Irpino, Italy.ORCID 0000-0003-4636-7695
L S PasqualeDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.ORCID 0009-0006-5104-956X
M S TathodeDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
G Li VoltiDepartment of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy. livolti@unict.it.ORCID 0000-0002-8678-2183
R MotterliniFaculty of Health, University Paris Est Créteil, INSERM, IMRB, Créteil, France.
F Di RaimondoDepartment of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, Italy.
D Tibullo *Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.ORCID 0000-0002-4416-8556
G A Palumbo *Department of Medical, Surgical Sciences and Advanced Technologies "G.F. Ingrassia", University of Catania, Catania, Italy.
University of Catania · ITPoliclinico Universitario di Catania · ITUniversity of Campania "Luigi Vanvitelli" · ITUniversity of Chieti-Pescara · ITBiogem · ITInserm · FRSaint Camillus International University of Health and Medical Sciences · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ineffective hematopoiesis is a hallmark of myelodysplastic syndromes (MDS). Hematopoietic alterations in MDS patients strictly correlate with microenvironment dysfunctions, eventually affecting also the mesenchymal stromal cell (MSC) compartment. Stromal cells are indeed epigenetically reprogrammed to cooperate with leukemic cells and propagate the disease as "tumor unit"; therefore, changes in MSC epigenetic profile might contribute to the hematopoietic perturbations typical of MDS. Here, we unveil that the histone variant macroH2A1 (mH2A1) regulates the crosstalk between epigenetics and inflammation in MDS-MSCs, potentially affecting their hematopoietic support ability. We show that the mH2A1 splicing isoform mH2A1.1 accumulates in MDS-MSCs, correlating with the expression of the Toll-like receptor 4 (TLR4), an important pro-tumor activator of MSC phenotype associated to a pro-inflammatory behavior. MH2A1.1-TLR4 axis was further investigated in HS-5 stromal cells after ectopic mH2A1.1 overexpression (mH2A1.1-OE). Proteomic data confirmed the activation of a pro-inflammatory signature associated to TLR4 and nuclear factor kappa B (NFkB) activation. Moreover, mH2A1.1-OE proteomic profile identified several upregulated proteins associated to DNA and histones hypermethylation, including S-adenosylhomocysteine hydrolase, a strong inhibitor of DNA methyltransferase and of the methyl donor S-adenosyl-methionine (SAM). HPLC analysis confirmed higher SAM/SAH ratio along with a metabolic reprogramming. Interestingly, an increased LDHA nuclear localization was detected both in mH2A1.1-OE cells and MDS-MSCs, probably depending on MSC inflammatory phenotype. Finally, coculturing healthy mH2A1.1-OE MSCs with CD34

Indexed as

Mesenchymal Stem CellsMyelodysplastic SyndromesNeoplasmsDNAEpigenesis, GeneticHistonesHumansInflammationProteomicsToll-Like Receptor 4Tumor MicroenvironmentDNAHistonesMACROH2A1 protein, humanToll-Like Receptor 4

Identifiers

PMID37852977
PMCPMC10584900
OpenAlexW4387734300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.